| 產(chǎn)品編號(hào) | bs-3106R-BF555 |
| 英文名稱 | Rabbit Anti-Phospho-EGFR (Ser1045)/BF555 Conjugated antibody |
| 中文名稱 | BF555標(biāo)記的磷酸化表皮生長(zhǎng)因子受體抗體 |
| 別 名 | EGFR(Phospho-Ser1045); EGFR (phospho Ser1045); EGFR (phospho S1045); p-EGFR (Ser1045); p-EGFR (S1045); EGFR; Avian erythroblastic leukemia viral (v erb b) oncogene homolog; Avian erythroblastic leukemia viral (verbb) oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog); Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian); Epidermal growth factor receptor; erbb 1; Erbb; Erbb1; HER1; mENA; Oncogene ERBB; PIG61; Receptor tyrosine protein kinase ErbB 1; Receptor tyrosine protein kinase ErbB1; Urogastrone; wa2; Wa5; EGFR_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 生長(zhǎng)因子和激素 細(xì)胞膜受體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, (predicted: Mouse, Rat, Horse, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 130kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human EGFR around the phosphorylation site of Ser1045 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Protein kinases are enzymes that transfer a phosphate group from a phosphate donor onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes, classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. Epidermal Growth factor receptor (EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma. Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action. Subunit: Binding of the ligand triggers homo- and/or heterodimerization of the receptor triggering its autophosphorylation. Heterodimer with ERBB2. Interacts with ERRFI1; inhibits dimerization of the kinase domain and autophosphorylation. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein coupling the receptor to downstream signaling pathways. Interacts with GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; mediates EGFR downstream signaling in cell proliferation. Interacts with RIPK1; involved in NF-kappa-B activation. Interacts (autophosphorylated) with CBL; involved in EGFR ubiquitination and regulation. Interacts with SOCS5; regulates EGFR degradation through TCEB1- and TCEB2-mediated ubiquitination and proteasomal degradation. Interacts with PRMT5; methylates EGFR and enhances interaction with PTPN6. Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of MAPK/ERK. Interacts with COPG; essential for regulation of EGF-dependent nuclear transport of EGFR by retrograde trafficking from the Golgi to the ER. Interacts with TNK2; this interaction is dependent on EGF stimulation and kinase activity of EGFR. Interacts with PCNA; positively regulates PCNA. Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 domains) with GRB2, NCK1 and NCK2. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome. Endosome membrane. Isoform 2: Secreted. Tissue Specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers. Post-translational modifications: Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occur. Methylated. Methylation at Arg-1199 by PRMT5 positively stimulates phosphorylation at Tyr-1197. DISEASE: Defects in EGFR are associated with lung cancer (LNCR) [MIM:211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily. Contains 1 protein kinase domain. Database links: Entrez Gene: 1956 Human Entrez Gene: 13649 Mouse Omim: 131550 Human SwissProt: P00533 Human SwissProt: Q01279 Mouse Unigene: 488293 Human Unigene: 420648 Mouse Unigene: 439882 Mouse Unigene: 8534 Mouse Unigene: 37227 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 細(xì)胞膜受體（Membrane Receptors) ????EGFR-血管內(nèi)皮生長(zhǎng)因子受體EGFR是一類分子量為170kDa的糖蛋白，在生長(zhǎng)的細(xì)胞包括中瘤細(xì)胞中跨越細(xì)胞質(zhì)膜，表現(xiàn)有蛋白激酶活性。 ????EGFR是一種細(xì)胞膜受體激酶，對(duì)血管內(nèi)皮生長(zhǎng)因子有高度的親和性，主要功能是參與血管內(nèi)皮細(xì)胞生長(zhǎng)和血管生成的調(diào)控,主要用于各種惡性腫瘤的研究.與其配體表皮生長(zhǎng)因子或尿抑胃素結(jié)合后則被激活，從而啟動(dòng)DNA及蛋白質(zhì)的合成。再不進(jìn)行有絲分裂的細(xì)胞中并不存在，但在胃中例外。 ????大量研究報(bào)道顯示，EGFR高表達(dá)的腫瘤生存降低、轉(zhuǎn)移風(fēng)險(xiǎn)增高、預(yù)后不良。在很多腫瘤中都存在著EGFR表達(dá)或過度表達(dá)。這些疾病包括：結(jié)直腸癌（CRC）、頭頸部鱗狀細(xì)胞癌（SCCHN）、乳腺癌、卵巢癌、宮頸癌、食道癌、胰腺癌、膀胱癌、前列腺癌和非小細(xì)胞肺癌等。研究表明，EGFR表達(dá)的腫瘤惡性程度增高、侵襲性強(qiáng)，這類腫瘤患者往往生存降低、轉(zhuǎn)移風(fēng)險(xiǎn)增高、預(yù)后不良。 |
